Figure 4

Clinical association between miR-132 and Aβ in Alzheimer’s disease.
(a–c) Correlation between miR-132 expression levels, insoluble Aβ42, Aβ plaque load in the ROS cohort and Sirt1 protein levels (n = 10–12 cases/group). (d–f) Correlation between miR-212 expression levels, insoluble Aβ42, Aβ plaque load in the ROS cohort and Sirt1 protein levels (n = 10–12 cases/group). (g) Correlation between Sirt1 protein levels and insoluble Aβ42 levels in the ROS cohort (n = 9–10 cases/group). (h) Western blot analysis of Sirt1 in non-demented controls and AD patients in the Douglas Bell Canada brain bank cohort (n = 8–11/group). Total proteins were used as normalization control. (i) Correlation between Sirt1 protein levels and miR-132 in the Douglas Bell Canada brain bank cohort (n = 6–9 cases/group). In (a–g,i) data are presented as exact P values (linear regression model). In (h) data are presented as P values, **P ≤ 0.01 (Mann-Whitney U test). Full-length blots/gels are presented in Supplementary Fig. S6.